Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $82.8 million.

  • Beam Therapeutics' Shares Outstanding (Weighted Average) rose 22.75% to $101.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.2 million, marking a year-over-year increase of 22.75%. This contributed to the annual value of $82.8 million for FY2024, which is 1.60% up from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Shares Outstanding (Weighted Average) is $82.8 million, which was up 1.60% from $81.5 million recorded in FY2023.
  • Beam Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $82.8 million for FY2024, and its period low was $58.0 million during FY2020.
  • For the 3-year period, Beam Therapeutics' Shares Outstanding (Weighted Average) averaged around $78.3 million, with its median value being $81.5 million (2023).
  • Data for Beam Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 17.54% (in 2021) over the last 5 years.
  • Over the past 5 years, Beam Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $58.0 million in 2020, then grew by 17.54% to $68.1 million in 2021, then increased by 3.42% to $70.5 million in 2022, then grew by 15.66% to $81.5 million in 2023, then increased by 1.60% to $82.8 million in 2024.